• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺 ER 阳性/HER2/neu 阴性浸润性导管癌的蛋白质组学分析和互作组分析:寻找蛋白质组学生物标志物。

Proteomic profiling and interactome analysis of ER-positive/HER2/neu negative invasive ductal carcinoma of the breast: towards proteomics biomarkers.

机构信息

Department of Chemistry, University of Pune, Ganeshkhind, Pune, India.

出版信息

OMICS. 2013 Jan;17(1):27-40. doi: 10.1089/omi.2012.0054.

DOI:10.1089/omi.2012.0054
PMID:23301641
Abstract

Breast cancer, especially ER positive/HER2/neu negative IDC, is the predominant subtype of invasive ductal carcinoma. Although proteomic approaches have been used towards biomarker discovery in clinical breast cancer, ER positive/HER2/neu negative IDC is the least studied subtype. To discover biomarkers, as well as to understand the molecular events associated with disease progression of estrogen receptor positive/HER2/neu negative subtype of invasive ductal carcinoma, differential protein expression profiling was performed by using LC-MS(E) (MS at elevated energy). A total of 118 proteins were identified, of which 26 were differentially expressed. These identified proteins were functionally classified and their interactions and coexpression were analyzed by using bioinformatic tools PANTHER (Protein Analysis THrough Evolutionary Relationships) and STRING (Search Tool for the Retrieval of Interacting Genes). These proteins were found to be upregulated and were involved in cytoskeletal organization, calcium binding, and stress response. Interactions of annexin A5, actin, S100 A10, glyceraldehyde 3 phosphate dehydrogenase, superoxide dismutase 1, apolipoprotein, fibrinogen, and heat shock proteins were prominent. Differential expression of these proteins was validated by two-dimensional gel electrophoresis and Western blot analysis. The cluster of these proteins may serve as a signature profile for estrogen receptor positive/ HER2/neu negative subtype.

摘要

乳腺癌,尤其是 ER 阳性/HER2/neu 阴性的 IDC,是最常见的浸润性导管癌亚型。尽管蛋白质组学方法已被用于临床乳腺癌的生物标志物发现,但 ER 阳性/HER2/neu 阴性 IDC 是研究最少的亚型。为了发现生物标志物,并了解与雌激素受体阳性/HER2/neu 阴性浸润性导管癌亚型疾病进展相关的分子事件,我们使用 LC-MS(E)(高能 MS)进行了差异蛋白表达谱分析。共鉴定出 118 种蛋白质,其中 26 种表达差异。这些鉴定出的蛋白质通过使用 PANTHER(通过进化关系进行蛋白质分析)和 STRING(搜索检索相互作用基因的工具)等生物信息学工具进行功能分类,并分析其相互作用和共表达。这些蛋白质被发现上调,并参与细胞骨架组织、钙结合和应激反应。膜联蛋白 A5、肌动蛋白、S100A10、甘油醛 3 磷酸脱氢酶、超氧化物歧化酶 1、载脂蛋白、纤维蛋白原和热休克蛋白的相互作用很突出。通过二维凝胶电泳和 Western blot 分析验证了这些蛋白质的差异表达。这些蛋白质的聚类可能成为雌激素受体阳性/HER2/neu 阴性亚型的特征谱。

相似文献

1
Proteomic profiling and interactome analysis of ER-positive/HER2/neu negative invasive ductal carcinoma of the breast: towards proteomics biomarkers.乳腺 ER 阳性/HER2/neu 阴性浸润性导管癌的蛋白质组学分析和互作组分析:寻找蛋白质组学生物标志物。
OMICS. 2013 Jan;17(1):27-40. doi: 10.1089/omi.2012.0054.
2
Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.与导管原位癌(DCIS)相关的浸润性乳腺导管癌与单纯浸润性乳腺癌中Her2/neu、类固醇受体(ER和PR)、Ki67和p53的表达情况。
Anticancer Res. 2005 May-Jun;25(3A):1719-23.
3
Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.乳腺导管癌中雌激素受体、孕激素受体及c-erbB2癌基因蛋白表达的改变
Cell Biol Int. 2008 Jun;32(6):698-707. doi: 10.1016/j.cellbi.2008.01.007. Epub 2008 Jan 25.
4
Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.导管浸润性乳腺癌——与激素受体和Her2/neu癌蛋白免疫组化表达相关的临床病理预后因素
Rom J Morphol Embryol. 2011;52(3 Suppl):1059-64.
5
Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue.发现并验证了 ER 阳性/Her2/neu 阴性的乳腺癌组织与配对的相邻正常乳腺组织之间的蛋白质差异。
Breast Cancer Res Treat. 2010 Nov;124(2):297-305. doi: 10.1007/s10549-009-0721-6. Epub 2010 Jan 20.
6
Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.乳腺癌蛋白质组学:细胞角蛋白19在人表皮生长因子受体2阳性乳腺肿瘤中的表达增强
Proteomics. 2005 May;5(7):1797-805. doi: 10.1002/pmic.200401069.
7
Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.ER 阳性、HER2 阳性和三阴性乳腺癌中的凋亡、增殖、免疫功能和耐药相关基因。
Neoplasma. 2012;59(4):424-32. doi: 10.4149/neo_2012_055.
8
Towards a proteome signature for invasive ductal breast carcinoma derived from label-free nanoscale LC-MS protein expression profiling of tumorous and glandular tissue.针对源自肿瘤和腺体组织无标记纳米级 LC-MS 蛋白质表达谱分析的浸润性导管乳腺癌的蛋白质组特征。
Anal Bioanal Chem. 2009 Dec;395(8):2443-56. doi: 10.1007/s00216-009-3187-9. Epub 2009 Oct 29.
9
Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.全球范围内与乳腺癌他莫昔芬耐药相关的信号转导网络的特征。
FEBS J. 2013 Nov;280(21):5237-57. doi: 10.1111/febs.12441. Epub 2013 Aug 19.
10
Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.乳腺癌基底样亚型的临床病理意义:与激素受体及Her2/neu过表达表型的比较
Hum Pathol. 2006 Sep;37(9):1217-26. doi: 10.1016/j.humpath.2006.04.015. Epub 2006 Jul 18.

引用本文的文献

1
Proteomics-Based Identification of Dysregulated Proteins and Biomarker Discovery in Invasive Ductal Carcinoma, the Most Common Breast Cancer Subtype.基于蛋白质组学鉴定浸润性导管癌(最常见的乳腺癌亚型)中失调的蛋白质并发现生物标志物
Proteomes. 2023 Apr 3;11(2):13. doi: 10.3390/proteomes11020013.
2
Proteomics and its applications in breast cancer.蛋白质组学及其在乳腺癌中的应用。
Am J Cancer Res. 2021 Sep 15;11(9):4006-4049. eCollection 2021.
3
Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10.
RAS 转化过程中的细胞表面蛋白酶激活:纤溶酶原受体 S100A10 的关键作用。
Oncotarget. 2016 Jul 26;7(30):47720-47737. doi: 10.18632/oncotarget.10279.
4
High plasma fibrinogen is correlated with poor response to trastuzumab treatment in HER2 positive breast cancer.高血浆纤维蛋白原与HER2阳性乳腺癌患者对曲妥珠单抗治疗反应不佳相关。
Medicine (Baltimore). 2015 Feb;94(5):e481. doi: 10.1097/MD.0000000000000481.
5
Profilin-1 overexpression in MDA-MB-231 breast cancer cells is associated with alterations in proteomics biomarkers of cell proliferation, survival, and motility as revealed by global proteomics analyses.通过全局蛋白质组学分析发现,MDA-MB-231乳腺癌细胞中丝切蛋白-1的过表达与细胞增殖、存活和运动的蛋白质组学生物标志物的改变有关。
OMICS. 2014 Dec;18(12):778-91. doi: 10.1089/omi.2014.0075.
6
Nanotheranostics for personalized medicine.用于个性化医疗的纳米诊疗剂。
Expert Rev Mol Diagn. 2013 Apr;13(3):257-69. doi: 10.1586/erm.13.15.